We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

April 14, 2022

Meeting snapshots - Expert insights from the HealthXL community

Commentary
Philip Connolly
&

Over the past month, our HealthXL community members met to discuss topics ranging from evidence gathering for Digital Therapeutics (DTx), to reimbursement  in the US, Software as a Medical Device (SaMD) regulation in the EU among others. 

We have curated some of the key takeaways from these sessions to showcase the top 5 expert insights from these meetings.

#1 On getting reimbursed in the US

When approaching payers to negotiate an access agreement, clinical data and cost-effectiveness are really important, especially the latter. But even when you have the evidence, becoming a trusted advisor for payers in the US is a huge challenge. The 4 key pillars of account management excellence when working with payers for DTx reimbursement are:

1) Customer interest

2) Seek mutual value creation

3) Bring an integrated team approach

4) Ongoing account management

 

Although there is still a long way to go to have clear and easy paths to reimbursement in the US, we are seeing new initiatives that point in the right direction. Recently, there has been a new PDT legislation introduced in the Congress, which has already moved to the finance committee and it is very clear on how it codifies PDT coverage in both Medicare and Medicaid, as well as proposed pricing and payment models. 

#2 On the challenges and best practices for evidence generation for DTx 

Aligning your evidence generation strategy with your commercialization strategy from the early stages is critical to avoid spending more money and time. Knowing who you want to sell to upfront is key to building an efficient and relevant evidence strategy. An approach that some DTx companies take initially is building a less regulated product and collecting real-world evidence. Once they have generated the evidence, they change towards the Software as a Medical Device (SaMD) model, hence a more regulated approach.

#3 On the regulation of Software as a Medical Device (SaMD) in Europe

Given the complexity of the new Medical Device Regulation (EU-MDR) for SaMD in terms of time to market, it can be easier for life sciences companies to start building  solutions that are not classified as medical devices and then build a roadmap towards class I, and then class II, or having only some parts of the solution that are SaMD. 

Artificial intelligence (AI) is still hard to fit in well with medical regulations. There are some changes expected to happen in Europe in the next few years. COCIR recently published a comprehensive paper, “AI in Medical Device Legislation", that focuses on AI-based devices in the scope of the EU MDR. The European Commission also published its proposal for the Artificial Intelligence Regulation (the Draft AI Regulation), which sets out plans for a comprehensive regulatory framework that covers AI systems in general.

#4 On the implementation and adoption of digital health in Oncology 

The combination of a relatively small oncology patient population overall combined with a wide diversity of disease and treatment types results in high levels of customization for small numbers of users or individual drugs. Combining this with distinct geographic differences in treatment paradigms has resulted in a perceived lack of scalability for digital therapeutics in oncology. 

Solutions surfaced in this context were devising ways to efficiently adapt a core solution to different disease types - demonstrating this would be valuable to both pharma partners and investors. Another idea was to take a disease agnostic approach and go directly to patients to get them engaged. Then, in turn, having these people push the tools onto the health care providers. 

#5 On clinical and economic evidence for standalone digital therapeutics (DTx) 

As software solutions, DTx will require ongoing monitoring and updates to fix bugs or improve features. As the industry evolves, there needs to be recognition that DTx products will be iterative - similar to other tech companies in sectors such as entertainment or banking. Non-prescription Standalone DTx, in particular, needs to be heavily consumer-focused and updated regularly to stay relevant. This creates issues as it may require multiple updates and resubmissions with regulators. 

Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Communities for access to polls and summaries from all of our meetings.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Standing Out from the Crowd in Economic Recession

14th February @ 10:45AM EDT

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Endpoints and Control Arms in Trials for DTx

15th February @ 10:45AM EDT

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

The Role of the Consumer Experience in DTx

15th February @ 10:45AM EDT

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Incorporating Extended Reality (XR) in Physician's’ Daily Work

28th February @ 10:45AM EDT

The healthcare industry is undergoing a digital transformation and extended reality (XR) technologies such as virtual reality (VR) and augmented reality (AR) are expected to play a significant role in this change in the next few years. Apply now to join this Masterclass led by Nemanja Kovačev, MedTech Expert at HTEC Group.

Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group
Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Health Meeting
7th February @ 10:45AM EDT

Product Differentiation for Digital Health Solutions in the Cardiometabolic Disease Area

In the past few years, digital health solutions have proven to be helpful in preventing and managing cardiometabolic diseases remotely, leading to better  health outcomes and less hospitalizations, emergency visits, and in-office visits.

Jenn Roberts
Featuring
Jenn Roberts
Vice President Employer Health Strategy, Hello Heart
Telemedicine & Virtual Care Delivery
9th February @ 10:45AM EDT

Business Opportunities for Digital Health in Autoimmune Conditions: Upcoming Blockbuster Drugs

Millions of people worldwide suffer from autoimmune conditions such as rheumatoid arthritis (RA), psoriasis, lupus, Crohn's disease, multiple sclerosis, atopic dermatitis, to name a few. Join this meeting to deep dive into this topic in the Immunology Meeting Series. Seats are limited so apply now to secure your place.

Erik Janssen
Featuring
Erik Janssen
VP Global Digital Care Transformation Immunology, UCB
Digital Therapeutics (DTx)
14th February @ 10:45AM EDT

Masterclass: Standing Out from the Crowd in Economic Recession

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Jeremy Sohn
Featuring
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
15th February @ 10:45AM EDT

Masterclass: Endpoints and Control Arms in Trials for DTx

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Acacia Parks
Featuring
Acacia Parks
Chief Science Officer, Twill

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.